



## Intersect ENT to Present at the 37th Annual J.P. Morgan Healthcare Conference

December 11, 2018

MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 11, 2018-- Intersect ENT, Inc. (Nasdaq: [XENT](#)), today announced that management will participate in the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at the Westin St. Francis Hotel in San Francisco, and will present at 4:30 p.m. PT.

A replay of the session will be available via the investors section of the company's website at [www.intersectENT.com](http://www.intersectENT.com). The webcast replay will be archived for approximately one month.

### **About Intersect ENT®**

Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

For additional information on the company or its products, including risks and benefits, please visit [www.IntersectENT.com](http://www.IntersectENT.com).

XENT-F

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181211005023/en/>

Source: Intersect ENT, Inc.

Jeri Hilleman  
650.641.2105  
[ir@intersectENT.com](mailto:ir@intersectENT.com)